HC Wainwright reaffirmed their buy rating on shares of Silence Therapeutics (NASDAQ:SLN – Free Report) in a research report released on Thursday, Benzinga reports. HC Wainwright currently has a $75.00 price objective on the stock.
Several other equities research analysts also recently commented on SLN. Morgan Stanley reaffirmed an overweight rating and set a $45.00 price objective on shares of Silence Therapeutics in a report on Monday, April 22nd. Chardan Capital restated a buy rating and set a $42.00 price target on shares of Silence Therapeutics in a research note on Friday, May 17th.
Get Our Latest Analysis on Silence Therapeutics
Silence Therapeutics Price Performance
Silence Therapeutics (NASDAQ:SLN – Get Free Report) last announced its quarterly earnings data on Thursday, May 16th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.18. The business had revenue of $15.73 million during the quarter, compared to analyst estimates of $4.53 million. Silence Therapeutics had a negative return on equity of 79.90% and a negative net margin of 131.44%. Equities analysts expect that Silence Therapeutics will post -1.52 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of SLN. Redmile Group LLC purchased a new stake in shares of Silence Therapeutics in the first quarter worth $43,798,000. Vivo Capital LLC increased its stake in Silence Therapeutics by 116.7% in the 1st quarter. Vivo Capital LLC now owns 1,105,454 shares of the company’s stock worth $23,878,000 after acquiring an additional 595,250 shares during the last quarter. Janus Henderson Group PLC purchased a new stake in shares of Silence Therapeutics in the 1st quarter valued at about $13,575,000. Lynx1 Capital Management LP boosted its position in shares of Silence Therapeutics by 123.4% during the 1st quarter. Lynx1 Capital Management LP now owns 526,642 shares of the company’s stock valued at $11,375,000 after acquiring an additional 290,855 shares during the last quarter. Finally, Parkman Healthcare Partners LLC grew its holdings in shares of Silence Therapeutics by 20.8% during the fourth quarter. Parkman Healthcare Partners LLC now owns 232,942 shares of the company’s stock worth $4,046,000 after purchasing an additional 40,063 shares in the last quarter. 98.73% of the stock is owned by institutional investors.
Silence Therapeutics Company Profile
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.
See Also
- Five stocks we like better than Silence Therapeutics
- How to Invest in Biotech Stocks
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- The How And Why of Investing in Oil Stocks
- MarketBeat Week in Review – 6/24 – 6/28
- What Do S&P 500 Stocks Tell Investors About the Market?
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.